VarmX
Developing hemostasis and thrombosis therapeutics to effectively restore hemostasis in individuals receiving oral factor Xa inhibitors.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | €15.0m Valuation: €150m | Late VC | |
| Total Funding | 000k | ||
Related Content
Developer of therapeutic drugs intended to restore blood clotting in bleeding patients. The company's drugs use modified recombinant human coagulation factor which is capable of restoring blood clotting in the presence of direct factor anticoagulants such as rivaroxaban, apixaban, and edoxaban, enabling physicians to safely and effectively restore hemostasis in case of bleeding.
Keywords: Pharmaceuticals and BiotechnologyBiotech Drugs, Blood Clotting, Blood Clotting Treatment, Blood Coagulation, Hemostasis Medicine, Hemostasis Technology, Therapeutic Drug, Therapeutics Development.